Peer Reviewed Publications

A list of selected articles authored by EEU Researchers that have been published in peer reviewed journals.

1. CME Review Article - The EEU model is presented to the international allergy community.

   Day, J.H. and Briscoe, M.P. The Environmental Exposure Unit. A system to test anti-allergic treatment.
   Ann Allergy Asthma Immunol (1999) 83: 83-93.
   Article Abstract

2. The role of allergen challenge chambers in the evaluation of anti-allergic medication: An international consensus paper.

   Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, Leynadier F, Lieberman P, Quirce P, Takenaka H, Van Cauwenberge P.
   Clin Exp Allergy Rev. (2006) 6: 31-59.
   

3. CME Review Article - Experimental models for the evaluation of treatment of allergic rhinitis.

   Day JH, Ellis AK, Rafeiro E, Ratz JD, Briscoe MP.
   Ann Allergy Asthma Immunol (2006) 96: 263-278.
   Article Abstract
   

   Editorial - "Methods for evaluation allergic rhinitis medications"

   Article in PDF

4. The Environmental Exposure Unit: A system to test anti-allergic treatment.

   Day JH. Clin Exp All Rev. (2003) 3: 82-86.
   Article Abstract

5. Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model.

   Day, J.H., Briscoe, M.P., Rafeiro, E., Ellis, A.K., Pettersson, E., Akerlund, A.
   J Allergy Clin Immunol. (2000) 105: 489-494.
   Article Abstract Article in PDF
   

   Selected as "Editor's Choice" (Editorial). - "No need to wait two weeks for relief."

   Article in PDF

6. Factors that affect the allergic rhinitis response to ragweed allergen exposure.

   Ellis AK, Ratz JD, Day AG, Day JH.
   Annals Allergy Asthma Immunol. 104:293-298, 2010.
   Article Abstract

7. Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit.

   Day JH, Briscoe MP, Ratz JD, Ellis AK, Yao R, Danzig M.
   Allergy Asthma Proc. 30:270-276, 2009.
   Article Abstract

8. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an Environmental Exposure Unit.

   Day JH, Briscoe MP, Ratz JD, Yao R, Danzig M.
   Annals Allergy Asthma Immunol. 102:328-338, 2009.
   Article Abstract Article in PDF

9. Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit.

   Day JH, Briscoe MP, Ratz JD.
   Allergy Asthma Proc. (2008) 29: 304-312. Epub 2008 Apr 2.
   Article in PDF

10. Comparison of the Rotorod to other air samplers for the determination of Ambrosia artemisiifolia pollen concentrations conducted in the Environmental Exposure Unit.

    Heffer MJ, Ratz JD, Miller JD, Day JH.
    Aerobiologia. (2005) 21: 233-239.
    Article Abstract Article Abstract
    Article in PDF

11. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the Environmental Exposure Unit.

    Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Frankish CW, Chapman D, deGuia EC, Kramer B, Warner C
    Allergy Asthma Proc. (2005) 26: 275-282.
    Article Abstract

12. Randomized, Double-Blind Comparison of Cetirizine and Fexofenadine after Pollen Challenge in the Environmental Exposure Unit (EEU): Duration of Effect in Subjects with Seasonal Allergic Rhinitis.

    Day, J.H., Briscoe, M.P., Rafeiro, E., Hewlett, D., Chapman, D., Kramer, B.
    Allergy Asthma Proc. (2004) 25: 59-68.
    Article Abstract

13. Comparative Clinical Efficacy, Onset and Duration of action of Levocetirizine and Desloratadine for Symptoms of Seasonal Allergic Rhinitis in Subjects Evaluated in the Environmental Exposure Unit (EEU).

    Day, J.H., Briscoe, M.P., Rafeiro, E., Ratz, J.D.
    Intl J Clin Pract. (2004) 58:109-118.
    Article Abstract

14. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed induced allergic rhinitis.

    Wilken, J.A., Kane R.L., Ellis, A.K. Rafeiro, E., Briscoe, M.P, Sullivan, C.L., Day, J.H.
    Ann Allergy Asthma Immunol. (2003) 91: 375-385.
    Article Abstract

15. Quality of life indices may be predictive of placebo and medication response to treatment for allergic rhinitis.

    Ellis, A.K., Rafeiro, E., Day, J.H.
    Ann Allergy Asthma Immunol. (2001). 86: 393-396.
    Article Abstract

16. Comparative Onset of Action and Symptom Relief with Cetirizine, Loratadine, or Placebo in an Environmental Exposure Unit in Subjects with Seasonal Allergic Rhinitis - Confirmation of a Test System.

    Day, J.H., Briscoe, M., Rafeiro, E., Chapman, M.S., Kramer, B.
    Ann Allergy Asthma Immunol. (2001) 87: 474-481.
    Article Abstract

17. Impact on quality of life during an allergen challenge research trial.

    Ellis, A.K., Day, J.H. and Lundie, M.J. Ann Allergy Asthma Immunol (1999) 83: 33-39.
    Article Abstract

18. Response to a Letter to the Editor: Outcomes of loratadine efficacy for SAR during environmental exposure.

    Day, J.H
    J Allergy Clin Immunol. (1999) 103: 715.
    Full Text Response.

19. Cetirizine, loratadine or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an Environmental Exposure Unit.

    Day, J.H., Briscoe, M.P. and Widlitz, M.
    J Allergy Clin Immunol. (1998) 101: 638-645.
    Article Abstract. Article in PDF

20. Onset of action, efficacy and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an Environmental Exposure Unit.

    Day, J.H., Briscoe, M.P., Welsh, A.C., Smith, J.N., Clark, A., Ellis, A.K. and Mason, J.
    Ann Allergy Asthma Immunol. (1997) 79: 533-540.
    Article Abstract.

21. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.

    Day, J.H., Briscoe, M. P., Clark, R.H., Ellis, A.K. and Gervais, P.
    Ann. Allergy Asthma Immunol. (1997) 79: 163-172.
    Article Abstract.

22. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure.

    Donovan, J.P., Buckeridge, D.L., Briscoe, M.P., Clark, R.H. and Day, J.H.
    Ann Allergy Asthma Immunol. (1996) 77: 74-80.
    Article Abstract.

23. A randomized, placebo-controlled, double-blind, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis.

    Day, J.H., Briscoe, M.P., Buckeridge, D.L., Clark, R.H., and Phillips, R.
    J Allergy Clin Immunol. (1996) 97: 1050-1057.
    Article Abstract. Article in PDF.

International Presentations

Introducing the EEU to the world...

Since 1995, Dr. James H. Day, the driving force behind the EEU and its continued development as a model for allergy research, has given over 90 presentations to the scientific and medical communities around the world. Below is a selection of those international presentations, lectures and seminars:

1. "The role of allergen challenge chambers in the evaluation of anti-allergic medication: An International Consensus."

   12th Biennial Allergy Abroad '06. Washington University in St. Louis School of Medicine CME. Switzerland, Germany, Alps and Bavaria. 20 Oct 2006.

2. "Experimental models for the evaluation of treatment of allergic rhinitis" and "The role of allergen challenge chambers in the evaluation of anti-allergen medication."

   XVI International Meeting of Asthma, Allergy and Immunology (Mitin Internacional de Asma, Alergia e Immunologia). Buenos Aires, Argentina. 01-03 Jun 2006.

3. "Placebo responses in clinical studies", "Factors affecting the allergic response to ragweed challenge" and "Novel approachs to allergen challenge."

   11th Biennial Allergy Abroad '04. Washington University in St. Louis School of Medicine CME. Italy and France. 06-08 Oct. 2004.

4. "Clinical efficacy of antihistamines using a controlled pollen exposure system: A comparison of desloratadine and levocetirizine."

   Symposium Series in Hyderabadah, Chennai, New Delhi, Kolkata and Mumbai, India. 7-11 Oct. 2003.

5. "Clinical efficacy of antihistamines using a controlled pollen exposure system: A comparison of desloratadine and levocetirizine."

   Annual Meeting of the European Academy of Allergology and Clinical Immunology (EAACI). Paris, France. 09 Jun. 2003.

6. "Novel approach to evaluate anti-allergic medications."

   Seminar: 60th Anniversary Meeting of the American Academy of Allergy, Asthma and Immunology (AAACI). Denver, CO. 08 Mar. 2003.

7. "Clinical efficacy of antihistamines and their evaluation using a controlled pollen exposure system."

   British Society for Immunology (BSI) and British Society for Allergy & Clinical Immunology (BSACI) Joint Congress. harrogate International Centre. Harrogate, UK 05 Dec. 2002.

8. "A randomized, double-blind, parallel group study of cetirizine HCl 10mg daily vs fexofenadine HCl 180mg daily vs placebo to determine onset of action and duration of effect in subjects with seasonal allergic rhinitis exposed to pollen challenge in an Environmental Exposure Unit (EEU)."

   Concurrent Session: Pharmacotherapy 1, 60th Annual Meeting, American College of Allergy, Asthma & Immunology (ACAAI). San Antonio, Texas. 15-20 Nov. 2002.

9. "Relevance of experimental models to clinical disease."

   58th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI). New York, NY. 03 Mar. 2002.

10. "Onset of action of nasal steroids."

    The American College of Allergy, Asthma & Immunology (ACAAI). Washington State Convention & Trade Center. Seattle, WA. 06 Nov. 2000.

11. "The Environmental Exposure Unit: A system to test anti-allergic treatment."

    International Congress of Allergy and Clinical Immunology 2000 Meeting. Sydney, Australia. 16 Oct 2000.

12. "EEU: A system to evaluate anti-allergic medications".

    Johns Hopkins Asthma & Allergy Center, Baltimore, MD. 14 Apr 2000.

13. "The Environmental Exposure Unit - A method of evaluating anti-allergic treatment."

    Paris, France 21 Oct 1999 and Mont Pellier, France 30 Oct 1999.

14. "The Environmental Exposure Unit: A method to test anti-allergic medication."

    8th Biennial Allergy Abroad: Faculty Exchange between Washington University, Queen's University, Seville University School of Medicine and Barcelona, Madrid. 13 Sep 1997.

15. "Efficacy of triamcinolone acetonide in seasonal allergic rhinitis."

    New Concepts in the Evaluation and Management of Rhinitis. The Annual Meeting of the European Academy of Allergology and Clinical Immunology. 29 May - 05 Jun 1997

16. "Onset of action of nasal corticosteroids and of four H1 specific antagonists using controlled antigen exposure."

    7th Biennial Allergy Abroad: Faculty Exchange between Washington University, Queen's University, Montpellier University, University of Vienna and Ilaynal Imre University of Health Science. Prague. 09 Oct 1995.

17. "Controlled Antigen Exposure - A means to assess effectiveness of anti-allergic medication."

    Joint International Symposium: New Trends in Allergy IV together with Environmental Allergy and Allergotoxicity III. Hamburg, Germany. 27 Apr - 01 May 1995.

18. "Comparison of onset of action and efficacy of cetirizine, terfenadine, loratadine, and astemizole as tested by controlled antigen challenge in an Environmental Exposure Unit."

    Plenary Session, New York Museum of Natural History. 01 Mar 1995.

Poster Presentations

Abstracts, Posters and other presentation material authored by the EEU. You may request a copy of this material by clicking Request Document in the menu on the left side of this page.

1. Day, J.H., Briscoe, M.P. and Lorber, R. Onset of action (OA) and efficacy of loratadine (LOR) vs placebo (P) in seasonal allergic rhinitis (SAR) subjects utilizing an Environmental Exposure Unit (EEU). (abstract #1014). J Allergy Clin Immunol. (1998) 101: S245.

2. Briscoe, M.P, Day, J.H., Rafeiro, E., Pettersson, E., Akerlund, A. Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model. (abstract #1134). J Allergy Clin Immunol. (2000) 104: S388.

3. Day, J.H., Briscoe, M.P., Rafeiro, E., Miller, C., Akerlund, A. A single-dose of budesonide 64 µG (Rhinocort® Aqua) is effective for severe allergic rhinitis symptoms in a controlled pollen exposure setting. (abstract #1024). J Allergy Clin Immunol (2001) 107: S313.

4. Day, J.H., Briscoe, M.P., Rafeiro, E., Chapman, D., Hewlett, D. A randomized, double-blind, parallel group study of cetirizine HCl 10 mg daily vs fexofenadine HCl 180 mg daily vs placebo to determine onset of action and duration of effect in subjects with seasonal allergic rhinitis exposed to pollen challenge in an Environmental Exposure Unit (EEU). (abstract #20) Ann Allergy Asthma Immunol. (2003) 90: 101.

5. Heffer, M.J., Ratz, J.D., Miller, J.D., Day, J.H. Comparison of the Rotorod sampler to three other methods for the determination of Ambrosia artemisiifolia pollen concentrations in the Environmental Exposure Unit. (abstract #689). J Allergy Clin Immunol. (2003) 111: S240.

6. Day JH, Briscoe MP, Rafeiro E, Schrewelius C, Simpson B, O’Dowd L. A comparison of rofleponide palmitate nasal spray (RPNS) with budesonide aqueous nasal spray (BANS) and placebo for seasonal allergic rhinitis (AR) using the Environmental Exposure Unit (EEU). (abstract # 703) J Allergy Clinical Immunol. (2004) 113: S202.

7. Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Chapman D, DeGuia E, Kramer B, Warner C. An evaluation of the efficacy of cetirizine, fexofenadine, and placebo, 5 to 12 hours post-dose, in ragweed allergic subjects with seasonal allergic rhinitis during pollen challenge in the Environmental Exposure Unit (EEU). (abstract P242) Ann Allergy Asthma Immunol. (2005) 94: 193.

8. Ellis AK, Ratz JD, Heffer MJ, Day JH. Seasonal Allergic Rhinitis: An evaluation of patient symptomatology and medication use during ragweed season. (abstract P243) Ann Allergy Asthma Immunol. (2005) 94: 193.

9. Ellis AK, Rafeiro E, Ratz JD, Day JH. The controlled allergen challenge experience: Comparison of allergic upper respiratory symptoms in the Environmental Exposure Unit (EEU) and during season exposure. (abstract P244) Ann Allergy Asthma Immunology. (2005) 94: 193.

10. Ellis AK, Ratz JD, Day A, Rafeiro E, Day JH. Factors affecting the allergic response to ragweed allergen challenge. (abstract P218) J Allergy Clin Immunol. 115: S54. Day JH, Briscoe MP, Ratz JD. Levocetirizine was superior to montelukast in controlling combined and most individual symptoms in subjects with seasonal allergic rhinitis in the Environmental Exposure Unit. (abstract #4) Ann Allergy Asthma Immunol. (2008) 100: A3.

11. Day JH, Briscoe MP, Ratz JD. Levocetirizine provided more consistent and satisfying symptom relief than montelukast in subjects with seasonal allergic rhinitis in the Environmental Exposure Unit. (abstract #6) Ann Allergy Asthma Immunol. (2008) 100:A4.

12. Ratz JD, Day JH, Briscoe MP. A placebo-controlled, four-way crossover study comparing azelastine nasal spray, cetirizine and loratadine in adult subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit (EEU). (abstract #P491) J Allergy Clin Immunol. (2009) 123: S129.

13. Ellis AK, Rafeiro E, Ratz JD, Day JH. The controlled allergen challenge experience: Comparison of allergic upper respiratory symptoms in the Environmental Exposure Unit (EEU) and during seasonal exposure. (abstract #28) Allergy Asthma Clin Immunol. (2009) 5(Suppl 1): 30.

14. Day JH, Briscoe MP, Ratz JD, Ellis AK, Danzig M, Yao R. Onset of action of loratadine/montelukast combination in subjects with seasonal allergic rhinitis in the Environmental Exposure Unit. (abstract #29) Allergy Asthma Clin Immunol. (2009) 5(Suppl 1): 30.

15. Ellis AK, Ratz JD, Chowdhury C, Day JH. Controlled allergen challenge clinical trials: Impact upon seasonal allergic rhinitis symptoms? (abstract P362) Annals Allergy Asthma Immunol. (2009) 103: A139.

16. Ellis AK, Ratz JD, Tebbutt SJ, Adamko DJ, Day JH. Phenotyping an allergic rhinitis population: Early and late phase responders to controlled allergen challenge in the Environmental Exposure Unit. (abstract #34) Annals Allergy Asthma Immunol. (2010) 105: A12.